Table 3. Cox Proportional HR of the Risk of Different Types of Antiplatelet and Anticoagulant Medications for Vitreous Hemorrhage in Patients with Non-Valvular Atrial Fibrillation.
| Warfarin (n=1188) | Antiplatelet agents (n=1474) | Warfarin+antiplatelet agents (n=1389) | |
|---|---|---|---|
| Events | 6 | 17 | 17 |
| Person years | 3355 | 3192 | 2357 |
| /1000 PYs (95% CI) | 1.79 (0.72–3.72) | 5.33 (3.20–8.35) | 7.21 (4.34–11.31) |
| HR (95% CI), p value | |||
| Unadjusted | 1 (Reference) | 4.58 (1.37–15.3), 0.013 | 4.17 (1.62–10.8), 0.003 |
| Clinical variable-adjusted* | 1 (Reference) | 4.64 (1.38–15.5), 0.013 | 4.15 (1.57–11.0), 0.004 |
CI, confidence interval; HR, hazard ratio; PYs, person years.
*Adjusted by age, gender, heart failure, hypertension, diabetes, stroke/transient ischemic attack, previous myocardial infarction, dyslipidemia, hemorrhagic stroke, valvular heart disease, malignancy, nonsteroidal anti-inflammatory drugs and corticosteroid medications.